# Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

> **NCT04978818** · PHASE4 · COMPLETED · sponsor: **Johns Hopkins Bloomberg School of Public Health** · enrollment: 333 (actual)

## Conditions studied

- Haemophilus Influenzae Type B Infection

## Interventions

- **DRUG:** Vaxelis
- **DRUG:** PedvaxHIB

## Key facts

- **NCT ID:** NCT04978818
- **Lead sponsor:** Johns Hopkins Bloomberg School of Public Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978818, "Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04978818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*